Specific Jak3 downregulation in lymphocytes impairs γ c cytokine signal transduction and alleviates antigen-driven inflammation in vivo

Molecular Therapy Nucleic Acids

Volumn 1, Issue 9, 2012, Pages e42-

  Gómez Valadés, Alicia G ^a   Llamas, María ^a   Blanch, Sílvia ^a   Perales, José C ^b   Román, Juan ^c   Gómez Casajús, Lluís ^c   Mascaró, Cristina ^a  

^a Discovery Biology Department   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Draconis Pharma SL Biology Department   (Spain)

Author keywords

Cytokines; Inflammation; RNA interference; T lymphocyte; Therapy

Indexed keywords

EID: 84868340987     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.37     Document Type: Article

References (50)

1. Johnston, JA, Kawamura, M, Kirken, RA, Chen, YQ, Blake, TB, Shibuya, K et al. (1994). Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370: 151-153. (Pubitemid 24229128)
2. Kawamura, M, McVicar, DW, Johnston, JA, Blake, TB, Chen, YQ, Lal, BK et al. (1994). Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 91: 6374-6378. (Pubitemid 24200663)
3. O'Shea, JJ, Pesu, M, Borie, DC and Changelian, PS (2004). A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555-564. (Pubitemid 39022985)
4. Baird, AM, Thomis, DC and Berg, LJ (1998). T cell development and activation in Jak3- deficient mice. J Leukoc Biol 63: 669-677. (Pubitemid 28274827)
5. Nosaka, T, van Deursen, JM, Tripp, RA, Thierfelder, WE, Witthuhn, BA, McMickle, AP et al. (1995). Defective lymphoid development in mice lacking Jak3. Science 270: 800-802.
6. Russell, SM, Tayebi, N, Nakajima, H, Riedy, MC, Roberts, JL, Aman, MJ et al. (1995). Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270: 797-800.
7. Soto, H, Hevezi, P, Roth, RB, Pahuja, A, Alleva, D, Acosta, HM et al. (2008). Gene array analysis comparison between rat collagen-induced arthritis and human rheumatoid arthritis. Scand J Immunol 68: 43-57. (Pubitemid 351798401)
8. Walker, JG, Ahern, MJ, Coleman, M, Weedon, H, Papangelis, V, Beroukas, D et al. (2007). Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/ STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 66: 992-999. (Pubitemid 47122309)
9. Kim, BH, Kim, M, Yin, CH, Jee, JG, Sandoval, C, Lee, H et al. (2011). Inhibition of JAK3 alleviates inflammation in monoarthritic rats. Br J Pharmacol 164: 106-118.
10. Coombs, JH, Bloom, BJ, Breedveld, FC, Fletcher, MP, Gruben, D, Kremer, JM et al. (2010). Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69: 413-416.
11. Kremer, JM, Bloom, BJ, Breedveld, FC, Coombs, JH, Fletcher, MP, Gruben, D et al. (2009). The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895-1905.
12. Busque, S, Leventhal, J, Brennan, DC, Steinberg, S, Klintmalm, G, Shah, T et al. (2009). Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 9: 1936-1945.
13. Karaman, MW, Herrgard, S, Treiber, DK, Gallant, P, Atteridge, CE, Campbell, BT et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
14. Changelian, PS, Moshinsky, D, Kuhn, CF, Flanagan, ME, Munchhof, MJ, Harris, TM et al. (2008). The specificity of JAK3 kinase inhibitors. Blood 111: 2155-2157. (Pubitemid 351451528)
15. Jiang, JK, Ghoreschi, K, Deflorian, F, Chen, Z, Perreira, M, Pesu, M et al. (2008). Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7Hpyrrolo[ 2,3-d]pyrimidin-4-yl) amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 51: 8012-8018.
16. Parganas, E, Wang, D, Stravopodis, D, Topham, DJ, Marine, JC, Teglund, S et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395. (Pubitemid 28232083)
17. Rodig, SJ, Meraz, MA, White, JM, Lampe, PA, Riley, JK, Arthur, CD et al. (1998). Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93: 373-383. (Pubitemid 28232082)
18. van Gurp, E, Weimar, W, Gaston, R, Brennan, D, Mendez, R, Pirsch, J et al. (2008). Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 8: 1711-1718.
19. Lin, TH, Hegen, M, Quadros, E, Nickerson-Nutter, CL, Appell, KC, Cole, AG et al. (2010). Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum 62: 2283-2293.
20. Haan, C, Rolvering, C, Raulf, F, Kapp, M, Drückes, P, Thoma, G et al. (2011). Jak1 has a dominant role over Jak3 in signal transduction through ?c-containing cytokine receptors. Chem Biol 18: 314-323.
21. Akhtar, S and Benter, IF (2007). Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117: 3623-3632. (Pubitemid 350224068)
22. Weinstein, S and Peer, D (2010). RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology 21: 232001.
23. Oberdoerffer, P, Kanellopoulou, C, Heissmeyer, V, Paeper, C, Borowski, C, Aifantis, I et al. (2005). Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages. Mol Cell Biol 25: 3896-3905. (Pubitemid 40617641)
24. Säemann, MD, Zeyda, M, Diakos, C, Szekeres, A, Böhmig, GA, Kelemen, P et al. (2003). Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 75: 1864-1872. (Pubitemid 36734644)
25. Tomita, K, Saijo, K, Yamasaki, S, Iida, T, Nakatsu, F, Arase, H et al. (2001). Cytokineindependent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex. J Biol Chem 276: 25378-25385.
26. Thomis, DC and Berg, LJ (1997). Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med 185: 197-206. (Pubitemid 27078277)
27. Ohta, A, Sato, N, Yahata, T, Ohmi, Y, Santa, K, Sato, T et al. (1997). Manipulation of Th1/ Th2 balance in vivo by adoptive transfer of antigen-specific Th1 or Th2 cells. J Immunol Methods 209: 85-92. (Pubitemid 28032147)
28. Feuerer, M, Eulenburg, K, Loddenkemper, C, Hamann, A and Huehn, J (2006). Self-limitation of Th1-mediated inflammation by IFN-gamma. J Immunol 176: 2857-2863.
29. Gust, TC, Neubrandt, L, Merz, C, Asadullah, K, Zügel, U and von Bonin, A (2008). RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genes. Cell Commun Signal 6: 3.
30. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
31. Novobrantseva, TI, Akinc, A, Borodovsky, A and de Fougerolles, A (2008). Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 11: 217-224. (Pubitemid 351281061)
32. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K and MacLachlan, I (2005). Sequence- dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462. (Pubitemid 41724921)
33. Sledz, CA, Holko, M, de Veer, MJ, Silverman, RH and Williams, BR (2003). Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839. (Pubitemid 37087172)
34. Schlee, M, Hornung, V and Hartmann, G (2006). siRNA and isRNA: two edges of one sword. Mol Ther 14: 463-470. (Pubitemid 44296098)
35. Cohney, SJ, Sanden, D, Cacalano, NA, Yoshimura, A, Mui, A, Migone, TS et al. (1999). SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 19: 4980-4988. (Pubitemid 29289537)
36. Jeffrey, JB, Nadia, JK, James, MM, Leila, NV, Artem L et al. (2012). Suppression of cytokine signaling by SOCS3: Characterization of the mode of inhibition and the basis of its specificity. Immunity 36: 239-250.
37. Brennan, FM and McInnes, IB (2008). Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545.
38. Bourquin, C, Anz, D, Zwiorek, K, Lanz, AL, Fuchs, S, Weigel, S et al. (2008). Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 181: 2990-2998.
39. Cekaite, L, Furset, G, Hovig, E and Sioud, M (2007). Gene expression analysis in blood cells in response to unmodified and 2?-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 365: 90-108. (Pubitemid 44830036)
40. Hegen, M, Keith, JC Jr, Collins, M and Nickerson-Nutter, CL (2008). Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67: 1505-1515.
41. Kirken, RA, Rui, H, Malabarba, MG, Howard, OM, Kawamura, M, O'Shea, JJ et al. (1995). Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine 7: 689-700.
42. Zhou, YJ, Magnuson, KS, Cheng, TP, Gadina, M, Frucht, DM, Galon, J et al. (2000). Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol Cell Biol 20: 4371-4380. (Pubitemid 30346631)
43. Tyner, JW, Walters, DK, Willis, SG, Luttropp, M, Oost, J, Loriaux, M et al. (2008). RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111: 2238-2245. (Pubitemid 351451431)
44. Fujii, H (2007). Cell type-specific roles of Jak3 in IL-2-induced proliferative signal transduction. Biochem Biophys Res Commun 354: 825-829. (Pubitemid 46186261)
45. Malabarba, MG, Kirken, RA, Rui, H, Koettnitz, K, Kawamura, M, O'Shea, JJ et al. (1995). Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4) stimulated proliferation and requires a membrane-proximal region of IL4 receptor alpha. J Biol Chem 270: 9630-9637.
46. De Souza, AT, Dai, X, Spencer, AG, Reppen, T, Menzie, A, Roesch, PL et al. (2006). Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res 34: 4486-4494. (Pubitemid 44567048)
47. Shi, M, Lin, TH, Appell, KC and Berg, LJ (2008). Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28: 763-773. (Pubitemid 351778407)
48. Kim, BH, Oh, SR, Yin, CH, Lee, S, Kim, EA, Kim, MS et al. (2010). MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol 148: 132-143.
49. Peer, D, Park, EJ, Morishita, Y, Carman, CV and Shimaoka, M (2008). Systemic leukocytedirected siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319: 627-630. (Pubitemid 351197066)
50. Murphy, KM, Heimberger, AB and Loh, DY (1990). Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250: 1720-1723. (Pubitemid 120031881)